The Myeloproliferative Neoplasms Channel is supported with funding from Takeda (Gold) and Kartos Therapeutics, Inc. (Bronze).
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
EHA 2021 | Interim analysis of add-on parsaclisib in myelofibrosis with suboptimal ruxolitinib response
Abdulraheem Yacoub, MD, University of Kansas Medical Center, Kansas City, MO, gives an update on a Phase II study (NCT02718300) evaluating the optimal dosing, efficacy and safety of add-on parsaclisib in patients with myelofibrosis who have a suboptimal response to ruxolitinib. Dr Yacoub gives an overview of the rationale for the study and comments on the key findings. Patients were randomized to receive either 10mg or 20mg once-daily (QD) for eight weeks and the same dose once-weekly thereafter. Dr Yacoub reports that add-on parsaclisib achieved further clinical benefit, persistent at six months of follow-up. This interview took place at the virtual European Hematology Association (EHA) Congress 2021.
